It depends on the standard you follow. As of September 2026, Gilead Sciences, Inc. (GILD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 13.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 3.37% / 30% · Interest income / Revenue 0.49% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 13.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.37% / 33% · Receivables / Mkt Cap (36m) 2.62% / 49% · Interest income / Revenue 0.49% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 13.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.37% / 33.33% · Receivables / Mkt Cap (24m) 2.62% / 33.33% · Interest income / Revenue 0.49% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 46.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 12.4% / 33.33% · Receivables / Avg Assets (4Q) 9.12% / 33.33% · Interest income / Revenue 0.49% / 5% | Fail |
| FTSE | Debt / Total Assets 51.0% / 33.33% · (Cash+ST Inv) / Total Assets 12.5% / 33.33% · (Cash+Recv) / Total Assets 22.3% / 33.33% · Interest income / Revenue 0.49% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Gilead Sciences, Inc. (GILD) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Gilead Sciences, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.49% of each dividend: Gilead Sciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
Gilead Sciences, Inc. (NASDAQ: GILD) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $207.9B. The Maz Rating grades it against the other companies in its sector.
Gilead Sciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $167.58, Gilead Sciences, Inc. trades at 6.7x sales and 16.0x book value, with an EV/EBITDA of 176.5. Over the last twelve months it generated about $31.0B of revenue and a net loss of $3.8B. It runs a gross margin of 79.9%, an operating margin of 34.5% and a net margin of -12.5%. It shows return on equity of -21.7%, return on invested capital of 25.6% and a free cash flow yield of 6.6%. On the balance sheet: a debt-to-equity ratio of 2.01 and a current ratio of 1.38. Over the past 52 weeks the share price ranged from $116.88 to $176.58, with a beta of 0.36.
Gilead Sciences, Inc. pays a dividend yielding 1.94%. Its Maz Dividend Score is 1.23 out of 5, ranked against the other dividend payers in its sector (Safety 1.50, Growth 2.17, Yield 3.57, Consistency 2.39).
58 Wall Street analyst ratings cover the stock: 38 Buy, 19 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.